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Introduction
The aim of the present study was to prospectively evaluate morbidity of intra-peritoneal hyperthermic chemotherapy (HIPEC) using Oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma and, secondly, to study peritoneal recurrence.
Methods
Between 2004 and 2007, 31 patients from 18 to 65 years with FIGO stage IIIC epithelial ovarian carcinoma were treated by surgery and a total of 6 cycles of platinum based chemotherapy.
Those patients were eligible for consolidation therapy. We performed a second look laparotomy operation with intraperitoneal hyperthermic chemotherapy. We used Oxaliplatin 460 mg/m2 with 2l/m2 of saline solution in a open medial laparotomy for a total of 30 minutes at a temperature of 42-44 degrees celcius.
Results
The grade 3 morbidity rate was 29% (95 CI : 14%-45%). Nine patients experienced a total of 13 exploratory laparotomies for intra-abdominal bleeding after HIPEC. Two-year disease free and overall survival were 27% and 67% respectively. As a result of this high level of morbidity the trial was closed.
Conclusion
Using intraperitoneal Oxaliplatin associated with hyperthermia as consolidation therapy for advanced ovarian cancer results in a high risk of grade 3 morbidities with only a small benefit on survival.
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INTRODUCTION
Epithelial ovarian cancer (EOC) is usually discovered at an advanced stage resulting in an overall poor prognosis for this condition. Modern first line treatment with debulking surgery which is as complete as possible and an intravenous combination of Paclitaxel and Platinum chemotherapy can result in remission in a majority of cases. Unfortunately, 50% of optimally debulked patients will recurre after a negative second look following 6 cycles of platinum based chemotherapy (1). Thus, overal survival will depend upon on 2 conditions: first, chemosensitivity and secondly, quality of cytoreductive surgery. Systemic treatment alone never results in cure, and so optimising surgery continues to be the best way to improve survival (2) . Intra-peritoneal chemotherapy (IPC) after optimal debulking surgery has been demonstrated as being beneficial in terms of overall and disease free survival with acceptable quality of life (3, 4, 5) . At this time a search for an effective consolidation treatment is required in order to control residual microscopic disease. So far none of the intra venous consolidation treatments have showed any survival benefits (6) . The use of IPC as consolidation therapy is suggestive of a treatment benefit but does not support a change in clinical practice (7) . On the other hand, IPC seems a very interesting and logical approach for a disease involving the peritoneal cavity. A consensus has emerged to support the potential benefit of hyperthermia associated with intraperitoneal chemotherapy (HIPEC) for the treatment of peritoneal carcinomatosis from colorectal origin (8).
Recent studies suggest some interest for the use of HIPEC in EOC patient (9) . Standard HIPEC is used at the time of debulking surgery. We have designed a study aimed to evaluate the HIPEC related morbidity as consolidation therapy for EOC patients. The grade 3 morbidity rate was 29% (95 CI : 14%-45%). Thirteen emergency laparotomies were performed on 9 patients for active intra-abdominal bleeding (IAB). Surgical characteristics of all patients with IAB are simmarized on table 3. These surgeries were performed between post operative day 3 and day 12 (with a median of 8 day). Six patients had one exploratory laparotomy. Two patients had two exploratory laparotomies. One patient had three exploratory laparotomies. Among those 9 patients with IAB, median platelet levels were 88500 (54000 to To date 24 patients have developed a recurrence.
DISCUSSION
This trial assessing cytoreductive surgery plus HIPEC with oxaliplatin was prematurely closed as there had been an unacceptably high rate of re-surgery for peritoneal haemorrhage. To test this combined treatment for EOC was logical when considering that HIPEC using Oxaliplatin and surgical resection cured approximately 25% of patients with peritoneal carcinomatosis from colorectal origin. This strategy was mainly applicable to patients with limited intraperitoneal cancer volume and no extraperitoneal involvement (12) . Platinum remains the most active drug class in ovarian cancer treatment. However, Oxaliplatin, a third-generation platinum derivative, has shown effective antitumor activity and a favorable toxicity profile in epithelial ovarian cancer (13) . Consolidation/maintenance therapy in the standard management of EOC remains controversial, primarily due to the unknown impact of this strategy on overall survival. The use of HIPEC after 6 cycles of chemotherapy may represent an interesting approach as the peritoneal cavity has been previously treated both surgically and medically. Therefore this could minimize the amount of intra-peritoneal disease. This is extremely important as it has been demonstrated that the effect of HIPEC reaches the centre of tumour deposits less than 3mm (14) . Extensive surgery associated with HIPEC usually impacts on morbidity. Therefore, our results reflect the side effects of HIPEC alone. 5 of the 8 centres involved in this study using HIPEC had more than 10 years of experience in this field. Unfortunately, in our series, surgical morbidity was a major issue. 9 patients developed post operative intra-abdominal bleeding (IAB) which was not incidentally associated with a less than 50000/ml platelets level. Other studies using Oxaliplatin following cytoreductive surgery and systemic chemotherapy (cisplatin-cyclophosphamide--six cycles). In a multicenter prospective trial, 29 patients with complete or optimal cytoreductive surgery and systemic treatment were included in the consolidation group and received HIPEC using cisplatin 100 mg/m2, for 60 min. The consolidation therapy group showed a better 5-year survival rate and lower recurrent disease rate, but differences were not statistically significant (19) . Our inclusion criteria included patients with poor prognostic factors: suboptimal (incomplete) debulking at first time laparotomy or positive second look. This could explain that overall and disease free survival rates are disapointing in this trial. Unfortunately HIPEC did not decrease the risk of peritoneal recurrence as 80% of our patients developed intra abdominal recurrence. As claimed in the recent paper of Helm et al, we still believe that HIPEC may be a future option in the management of advanced epithelial ovarian cancer. The choice of appropriate drugs will be the key point.
In conclusion, this phase II trial showed a dramatic rate of morbidity that fortunately did not affect perioperative mortality. We were unable to demonstrate any survival benefit following this M A N U S C R I P T Overall and Recurrence free survival
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